WAY-318068: A novel, potent and selective noradrenaline re-uptake inhibitor with activity in rodent models of pain and depression

British Journal of Pharmacology

Volumn 160, Issue 5, 2010, Pages 1105-1118

  Whiteside, G T ^a   Dwyer, J M ^a   Harrison, J E ^a   Beyer, C E ^a   Cummons, T ^a   Manzino, L ^a   Mark, L ^a   Johnston, G H ^a   Strassle, B W ^a   Adedoyin, A ^a   Lu, P ^a   Piesla, M J ^a   Pulicicchio, C M ^a   Erve, J C L ^a   Platt, B J ^a   Hughes, Z A ^a   Rogers, K E ^a   Deecher, D C ^a   Trybulski, E J ^a   Kennedy, J D ^a   Zhang, P ^a   Leventhal, L ^a   more..

^a PFIZER INC   (United States)

Author keywords

5 HT; Depression; Noradrenaline; NRI; Pain; SNRI

Indexed keywords

1 [1 (3,5 DIFLUOROPHENYL) 2 HYDROXY 3 (METHYLAMINO)PROPYL] 7 FLUORO 3,3 DIMETHYL 1,3 DIHYDRO 2H INDOL 2 ONE; CELECOXIB; DESIPRAMINE; DULOXETINE; GABAPENTIN; INDOMETACIN; MORPHINE; NORADRENALIN; NORADRENALIN TRANSPORTER; NORADRENALIN UPTAKE INHIBITOR; REBOXETINE; SEROTONIN; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; WAY 318068; ADRENERGIC RECEPTOR AFFECTING AGENT; DOPAMINE TRANSPORTER; INDOLE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; WAY-318068;

ALLODYNIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING ASSAY; BONE CANCER; BONE PAIN; BRAIN CORTEX; CANCER PAIN; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DOSE RESPONSE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG POTENCY; DRUG SELECTIVITY; HUMAN; HUMAN CELL; HYPERALGESIA; IC 50; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MALE; MICRODIALYSIS; MOUSE; NEUROPATHIC PAIN; NONHUMAN; NORADRENALIN BRAIN LEVEL; OSTEOARTHRITIS; PAIN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; VISCERAL PAIN; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECTS; INBRED MOUSE STRAIN; METABOLISM; ORAL DRUG ADMINISTRATION; PAIN MEASUREMENT; PROCEDURES; SPRAGUE DAWLEY RAT; TRANSFORMED CELL LINE;

ADMINISTRATION, ORAL; ADRENERGIC UPTAKE INHIBITORS; ANIMALS; CELL LINE, TRANSFORMED; CEREBRAL CORTEX; DEPRESSION; DISEASE MODELS, ANIMAL; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; INDOLES; MALE; MICE; MICE, INBRED STRAINS; NOREPINEPHRINE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PAIN; PAIN MEASUREMENT; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 77953189418     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00690.x     Document Type: Article

References (47)

1. Alexander SPH, Mathie A, Peters JA (2009). Guide to Receptors and Channels (GRAC), 4th edition. Br J Pharmacol 158 : S1 S239.
2. Anjaneyulu M, Chopra K (2004). Fluoxetine attenuates thermal hyperalgesia through 5-HT1/2 receptors in streptozotocin-induced diabetic mice. Eur J Pharmacol 497 : 285 292.
3. Beique JC, Lavoie N, de Montigny C, Debonnel G (1998). Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Eur J Pharmacol 349 : 129 132.
4. Bingham B, Jones PG, Uveges AJ, Kotnis S, Lu P, Smith VA et al. (2007). Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers. Br J Pharmacol 151 : 1061 1070.
5. Bomholt SF, Mikkelsen JD, Blackburn-Munro G (2005). Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain. Neuropharmacology 48 : 252 263.
6. Burgess SE, Gardell LR, Ossipov MH, Malan TP, Vanderah TW, Lai J et al. (2002). Time-dependent descending facilitation from the rostral ventromedial medulla maintains, but does not initiate, neuropathic pain. J Neurosci 22 : 5129 5136.
7. Bymaster FP, Lee TC, Knadler MP, Detke MJ, Iyengar S (2005). The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr Pharm Des 11 : 1475 1493.
8. Caggiula AR, Epstein LH, Perkins KA, Saylor S (1995). Different methods of assessing nicotine-induced antinociception may engage different neural mechanisms. Psychopharmacology 122 : 301 306.
9. Chandran P, Pai M, Blomme EA, Hsieh GC, Decker MW, Honore P (2009). Pharmacological modulation of movement-evoked pain in a rat model of osteoarthritis. Eur J Pharmacol 613 : 39 45.
10. Chappell AS, Ossanna MJ, Liu-Seifert H, Iyengar S, Skljarevski V, Li LC et al. (2009). Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial. Pain 146 : 253 260.
11. Chen ZM, Skolnick P (2007). Triple uptake inhibitors: therapeutic potential in depression and beyond. Expert Opin Investig Drugs 16 : 1365 1377.
12. Collins SL, Moore RA, McQuay HJ, Wiffen P (2000). Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manage 20 : 449 458.
13. El Mouedden M, Meert TF (2007). Pharmacological evaluation of opioid and non-opioid analgesics in a murine bone cancer model of pain. Pharmacol Biochem Behav 86 : 458 467.
14. Erve JCL, Beyer CE, Manzino L, Talaat RE (2009). Metabolite identification in rat brain microdialysates by direct infusion nanoelectrospray ionization after desalting on a ZipTip and LTQ/Orbitrap mass spectrometry. Rapid Commun Mass Spectrom 23 : 4003 4012.
15. Fishbain DA, Cutler R, Rosomoff HL, Rosomoff RS (2000). Evidence-based data from animal and human experimental studies on pain relief with antidepressants: a structured review. Pain Med 1 : 310 316.
16. Gabra BH, Merino VF, Bader M, Pesquero JB, Sirois P (2005). Absence of diabetic hyperalgesia in bradykinin B-1 receptor-knockout mice. Regul Pept 127 : 245 248.
17. Gebhart GF (1993). Descending modulation of spinal nociceptive processing. Schmerz 7 : 216 225.
18. Gilmor ML, Owens MJ, Nemeroff CB (2002). Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Am J Psychiatry 159 : 1702 1710.
19. Hajos M, Fleishaker JC, Filipiak-Reisner JK, Brown MT, Wong EHF (2004). The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. CNS Drug Rev 10 : 23 44.
20. Holden JE, Schwartz EJ, Proudfit HK (1999). Microinjection of morphine in the A7 catecholamine cell group produces opposing effects on nociception that are mediated by alpha1- and alpha2-adrenoceptors. Neuroscience 91 : 979 990.
21. Ikeda T, Ishida Y, Naono R, Takeda R, Abe H, Nakamura T et al. (2009). Effects of intrathecal administration of newer antidepressants on mechanical allodynia in rat models of neuropathic pain. Neurosci Res 63 : 42 46.
22. Isenberg KE, Cicero TJ (1984). Possible involvement of opiate receptors in the pharmacological profiles of antidepressant compounds. Eur J Pharmacol 103 : 57 63.
23. Jones CK, Peters SC, Shannon HE (2005). Efficacy of duloxetine, a potent and balanced serotonergic and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents. J Pharmacol Exp Ther 312 : 726 732.
24. LaBuda CJ, Little PJ (2005). Pharmacological evaluation of the selective spinal nerve ligation model of neuropathic pain in the rat. J Neurosci Methods 144 : 175 181.
25. Leventhal L, Smith V, Hornby G, Andree TH, Brandt MR, Rogers KE (2007). Differential and synergistic effects of selective norepinephrine and serotonin reuptake inhibitors in rodent models of pain. J Pharmacol Exp Ther 320 : 1178 1185.
26. McComas CC, Mahaney PE, Cohn ST, Coghlan RD, Fensome A, Heffernan GD et al. (2008). Synthesis and activity of 1-(3-amino-2-hydroxy-1-phenylpropyl) indolin-2-ones: discovery of selective norepinephrine reuptake inhibitor WAY-315193 (NRI-193). 31st National Medicinal Chemistry Symposium, University of Pittsburgh, Pittsburgh, PA.
27. Mahaney PE, Heffernan GD, Coghlan RD, Cohn ST, Kim CY, Jenkins DJ et al. (2007). Phenylaminopropanol derivatives as monoamine reuptake inhibitors and their preparation, pharmaceutical compositions and use in the treatment of disease ameliorated by monoamine reuptake. Vol. US 2007072897.
28. Mahaney PE, Gavrin LK, Trybulski EJ, Stack GP, Vu AT, Cohn ST et al. (2008). Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors. J Med Chem 51 : 4038 4049.
29. Michael-Titusa A, Costentin J (1987). Analgesic effects of metapramine and evidence against the involvement of endogenous enkephalins in the analgesia induced by tricyclic antidepressants. Pain 31 : 391 400.
30. Millan MJ (2002). Descending control of pain. Prog Neurobiol 66 : 355 474.
31. Nicholson B, Verma S (2004). Comorbidities in chronic neuropathic pain. Pain Med 5 : S9 S27.
32. Nielsen CK, Lewis RJ, Alewood D, Drinkwater R, Palant E, Patterson M et al. (2005). Anti-allodynic efficacy of the chi-conopeptide, Xen2174, in rats with neuropathic pain. Pain 118 : 112 124.
33. Onghena P, Vanhoudenhove B (1992). Antidepressant-induced analgesia in chronic nonmalignant pain - a metaanalysis of 39 placebo-controlled studies. Pain 49 : 205 219.
34. Owens MJ, Knight DL, Nemeroff CB (2000). Paroxetine binding to the rat norepinephrine transporter in vivo. Biol Psychiatry 47 : 842 845.
35. Paxinos G, Watson C (1986). Rat Brain in Stereotactic Coordinates, 2nd edn. Academic Press
36. Pedersen LH, Nielsen AN, Blackburn-Munro G (2005). Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in rat models of persistent and neuropathic pain. Psychopharmacology 182 : 551 561.
37. Pomonis JD, Boulet JM, Gottshall SL, Phillips S, Sellers R, Bunton T et al. (2005). Development and pharmacological characterization of a rat model of osteoarthritis pain. Pain 114 : 339 346.
38. Ren K, Dubner R (2002). Descending modulation in persistent pain: an update. Pain 100 : 1 6.
39. Rubinstein M, Mogil JS, Japon M, Chan EC, Allen RG, Low MJ (1996). Absence of opioid stress-induced analgesia in mice lacking beta-endorphin by site-directed mutagenesis. Proc Natl Acad Sci USA 93 : 3995 4000.
40. Sanchez C, Hyttel J (1999). Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 19 : 467 489.
41. Siegmund E, Cadmus R, Lu G (1957). A method for evaluating both non-narcotic and narcotic analgesics. Proc Soc Exp Biol Med 95 : 729 731.
42. Sullivan NR, Leventhal L, Harrison J, Smith VA, Cummons TA, Spangler TB et al. (2007). Pharmacological characterization of the muscarinic agonist (3R,4R)-3-(3-hexylsulfanyl-pyrazin-2-yloxy)-1-azabicyclo2.2.1 heptane (WAY-132983) in in vitro and in vivo models of chronic pain. J Pharmacol Exp Ther 322 : 1294 1304.
43. Vu AT, Cohn ST, Zhang PW, Kim C, Mahaney PE, Bray J et al. (2009). ACS1-(indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors. J Med Chem 53 : 205 262.
44. Zhang P, Cohn ST, Coghlan RD, Fensome A, Heffernan GD, Kim C et al. (2009a). Synthesis and activity of 1-(3-amino-2-hydroxy-1-phenylpropyl) indolin-2-ones and derivatives: discovery of selective norepinephrine reuptake inhibitor WAY-318068. 9th Winter Conference on Medicinal & Bioorganic Chemistry, Steamboat Springs, CO.
45. Zhang PW, Terefenko EA, Bray J, Deecher D, Fensome A, Harrison J et al. (2009b). 1-or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol- 2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors. J Med Chem 52 : 5703 5711.
46. Zhao ZQ, Chiechio S, Sun YG, Zhang KH, Zhao CS, Scott M et al. (2007). Mice lacking central serotonergic neurons show enhanced inflammatory pain and an impaired analgesic response to antidepressant drugs. J Neurosci 27 : 6045 6053.
47. Zhuo M, Gebhart GF (1991). Spinal serotonin receptors mediate descending facilitation of a nociceptive reflex from the nuclei reticularis- gigantocellularis and gigantocellularis pars-alpha in the rat. Brain Res 550 : 35 48.